Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite Formation

(S)-5-Chloro-1-(1-cyclopropylethyl)-3-(2,6-dichloro-4-(trifluoromethyl)phenylamino)pyrazin-2(1H)-one (BMS-665053), a pyrazinone-containing compound, is a potent and selective antagonist of corticotropin-releasing factor receptor-1 (CRF-R1) that showed efficacy in the defensive withdrawal model for anxiety in rats, suggesting its use as a potential treatment for anxiety and depression. In vitro metabolism studies of BMS-665053 in rat and human liver microsomes revealed cytochrome P450-mediated oxidation of the pyrazinone moiety, followed by ring opening, as the primary metabolic pathway. Detection of a series of GSH adducts in trapping experiments suggested the formation of a reactive intermediate, probably as a result of epoxidation of the pyrazinone moiety. In addition, BMS-665053 (20 mg/kg i.v.) underwent extensive metabolism in bile duct-cannulated (BDC) rats. The major drug-related materials in rat plasma were the pyrazinone oxidation products. In rat bile and urine (0–7 h), only a trace amount of the parent drug was recovered, whereas significant levels of the pyrazinone epoxide-derived metabolites and GSH-related conjugates were detected. Further evidence suggested that GSH-related conjugates also formed at the dichloroarylamine moiety possibly via an epoxide or a quinone imine intermediate. Other major metabolites in BDC rat bile and urine included glucuronide conjugates. To reduce potential liability due to metabolic activation of BMS-665053, a number of pyrazinone analogs with different substituents were synthesized and investigated for reactive metabolite formation, leading to the discovery of a CRF-R1 antagonist with diminished in vitro metabolic activation.

[1]  Charles C. Lin,et al.  Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMR. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  K. Lewis,et al.  Expression cloning of a human corticotropin-releasing-factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Paul E. Sawchenko,et al.  Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress , 2000, Nature Genetics.

[4]  Vijay T. Ahuja,et al.  In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. , 2009, Journal of medicinal chemistry.

[5]  Kathryn A. Ward,et al.  The anxiolytic CRF1 antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats , 2003, Psychopharmacology.

[6]  T. Baillie,et al.  Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological mass spectrometry.

[7]  G. Koob,et al.  Corticotropin Releasing Factor Receptor 1–Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development , 1998, Neuron.

[8]  T. Baillie,et al.  Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. , 2003, Chemical research in toxicology.

[9]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[10]  G. Koob,et al.  Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1 1 Published on the World Wide Web on 27 November 1998. 1 , 1999, Brain Research.

[11]  Daniel R McMasters,et al.  Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. , 2003, Journal of medicinal chemistry.

[12]  P. Gilligan,et al.  The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats , 2002, Psychopharmacology.

[13]  Lawrence C Kuo,et al.  Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization. , 2005, Bioorganic & medicinal chemistry letters.

[14]  C. Gibson,et al.  In vitro metabolism of a thrombin inhibitor and quantitation of metabolically generated cyanide. , 2005, Journal of pharmaceutical and biomedical analysis.

[15]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. , 1982, Science.

[16]  Darci M. Nielsen.  Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? , 2006, Life sciences.

[17]  F. Holsboer,et al.  The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. , 1999, Journal of psychiatric research.

[18]  Florian Holsboer,et al.  CRF signaling: molecular specificity for drug targeting in the CNS. , 2006, Trends in pharmacological sciences.

[19]  M. Mathieu,et al.  Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation. , 2004, Bioorganic & medicinal chemistry letters.

[20]  Susan E. Murray,et al.  Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2 , 2000, Nature Genetics.

[21]  J. Vacca,et al.  Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. , 1998, Journal of medicinal chemistry.

[22]  F. Holsboer,et al.  Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. , 1999, Journal of psychiatric research.

[23]  H. Frierson,et al.  Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[24]  Joseph Payne,et al.  Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. , 2009, Journal of medicinal chemistry.

[25]  F. Holsboer,et al.  Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 , 1998, Nature Genetics.

[26]  A. Gorman,et al.  The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[27]  R. Pauwels,et al.  Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. , 2005, Journal of medicinal chemistry.

[28]  T. Lovenberg,et al.  Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior , 1997, Regulatory Peptides.

[29]  C. Bayly,et al.  Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[30]  Florian Holsboer,et al.  Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. , 2003, Journal of psychiatric research.

[31]  W. Vale,et al.  CRF and CRF receptors: role in stress responsivity and other behaviors. , 2004, Annual review of pharmacology and toxicology.